Nymox Pharmaceutical Corp
OTC:NYMXF
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
N
|
Nymox Pharmaceutical Corp
OTC:NYMXF
|
CA |
|
Power Metals Corp
XTSX:PWM
|
CA |
|
Draytek Corp
TWSE:6216
|
TW |
Nymox Pharmaceutical Corp
Nymox Pharmaceutical Corp. operates as a biopharmaceutical company, which engages in the research and development on products for the aging population. The company is headquartered in Saint-Laurent, Quebec and currently employs 3 full-time employees. The firm is focused on developing its drug candidate, NX-1207, for the treatment of benign prostatic hyperplasia (BPH) and the treatment of low-grade localized prostate cancer. The firm operates through the research and development of products for the aging population segment. The firm markets NicAlert and TobacAlert tests that use urine or saliva to detect use of tobacco products. The firm also owns rights for its marketed products, its investigational drug, as well as other therapeutic and diagnostic indications. The firm also has the rights for the use of statin drugs for the treatment and prevention of Alzheimer's disease. The firm's subsidiaries include Nymox Corporation and Serex, Inc. The Company’s Nymox Corporation conducts research and development, while Serex, Inc. conducts research and development, and manufacturing of NicAlert and TobacAlert.
Nymox Pharmaceutical Corp. operates as a biopharmaceutical company, which engages in the research and development on products for the aging population. The company is headquartered in Saint-Laurent, Quebec and currently employs 3 full-time employees. The firm is focused on developing its drug candidate, NX-1207, for the treatment of benign prostatic hyperplasia (BPH) and the treatment of low-grade localized prostate cancer. The firm operates through the research and development of products for the aging population segment. The firm markets NicAlert and TobacAlert tests that use urine or saliva to detect use of tobacco products. The firm also owns rights for its marketed products, its investigational drug, as well as other therapeutic and diagnostic indications. The firm also has the rights for the use of statin drugs for the treatment and prevention of Alzheimer's disease. The firm's subsidiaries include Nymox Corporation and Serex, Inc. The Company’s Nymox Corporation conducts research and development, while Serex, Inc. conducts research and development, and manufacturing of NicAlert and TobacAlert.
